tetano
Editor, Senior Moderator
Curr Microbiol
. 2023 May 24;80(7):223.
doi: 10.1007/s00284-023-03315-y. Interaction Between SARS-CoV-2 and Pathogenic Bacteria
Parvindokht Fazel[SUP] #[/SUP][SUP] 1 2 [/SUP], Hamid Sedighian[SUP] #[/SUP][SUP] 3 [/SUP], Elham Behzadi[SUP] 4 [/SUP], Reza Kachuei[SUP] 5 [/SUP], Abbas Ali Imani Fooladi[SUP] 6 [/SUP]
Affiliations
The novel human coronavirus, Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), which results in the coronavirus disease 2019 (COVID-19), has caused a serious threat to global public health. Therefore, many studies are performed on the causes and prevalence of this disease and the possible co-occurrence of the infection with other viral and bacterial pathogens is investigated. Respiratory infections predispose patients to co-infections and these lead to increased disease severity and mortality. Numerous types of antibiotics have been employed for the prevention and treatment of bacterial co-infection and secondary bacterial infections in patients with a SARS-CoV-2 infection. Although antibiotics do not directly affect SARS-CoV-2, viral respiratory infections often result in bacterial pneumonia. It is possible that some patients die from bacterial co-infection rather than virus itself. Therefore, bacterial co-infection and secondary bacterial infection are considered critical risk factors for the severity and mortality rates of COVID-19. In this review, we will summarize the bacterial co-infection and secondary bacterial infection in some featured respiratory viral infections, especially COVID-19.
. 2023 May 24;80(7):223.
doi: 10.1007/s00284-023-03315-y. Interaction Between SARS-CoV-2 and Pathogenic Bacteria
Parvindokht Fazel[SUP] #[/SUP][SUP] 1 2 [/SUP], Hamid Sedighian[SUP] #[/SUP][SUP] 3 [/SUP], Elham Behzadi[SUP] 4 [/SUP], Reza Kachuei[SUP] 5 [/SUP], Abbas Ali Imani Fooladi[SUP] 6 [/SUP]
Affiliations
- PMID: 37222840
- DOI: 10.1007/s00284-023-03315-y
The novel human coronavirus, Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), which results in the coronavirus disease 2019 (COVID-19), has caused a serious threat to global public health. Therefore, many studies are performed on the causes and prevalence of this disease and the possible co-occurrence of the infection with other viral and bacterial pathogens is investigated. Respiratory infections predispose patients to co-infections and these lead to increased disease severity and mortality. Numerous types of antibiotics have been employed for the prevention and treatment of bacterial co-infection and secondary bacterial infections in patients with a SARS-CoV-2 infection. Although antibiotics do not directly affect SARS-CoV-2, viral respiratory infections often result in bacterial pneumonia. It is possible that some patients die from bacterial co-infection rather than virus itself. Therefore, bacterial co-infection and secondary bacterial infection are considered critical risk factors for the severity and mortality rates of COVID-19. In this review, we will summarize the bacterial co-infection and secondary bacterial infection in some featured respiratory viral infections, especially COVID-19.